It diminishes Gram-negative bacteria such as Bacteroidetes, Proteobacteria, and Fusobacteria, lowers endotoxin concentration in serum, enhances the structure of gut microbiota, and boosts SOD activity in serum by 29.1%
Clinically meaningful outcomes in AD/ADRD trials
Diabetologia 110 Hernn MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, Robins JM (2008) Observational studies analyzed like randomized experiments:an application to postmenopausal hormone therapy and coronary heart disease
10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people living with obesity or overweight in Phase 3 trial In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1 The trial met both weight loss primary endpoints and its key secondary endpoint evaluating waist circumference, a predictor of cardiometabolic risk, together demonstrating survodutide's potential to broadly improve metabolic health1 In addition to these positive results, Boehringer is advancing its broad metabolic health R&D program, exploring multiple pharmaceutical approaches to weight management including oral treatments
She is highly skilled in injectables, and her must-have skincare product is Plated for its incredible, transformative results across all skin types
